Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD) (S56.007)

Conclusions:Deutetrabenazine at 24 mg/day and 36 mg/day provided clinically significant benefits, including reduction in abnormal involuntary movements on AIMS. Improvements were appreciated by clinicians, shown by improvements on the CGIC. Fixed-dose deutetrabenazine was generally well tolerated.Study Supported by:This study was funded by Teva Branded Pharmaceutical Products R&D, Inc. Petach Tikva, IsraelDisclosure: Dr. Anderson has received personal compensation for activities with LEGATO-HD, AIM-TD, ARM-TD studies. Pride-HD, First-HD, ARC-HD, and Teva CNS> Dr. Stamler has received personal compensation for activities with Auspex Pharma as an employee. Dr. Davis has received personal compensation for activities with Teva Pharmaceuticals as an employee. Dr. Factor has received personal compensation for activities with Lundbeck, TEVA, Neurocrine, Avanir, Cynapsus, and Adamas as a consultant and from Uptodate as a speaker. Dr. Factor has received research support from Ipsen, Auspex/Teva, US World Meds, Pharm-Olam, Cynapsus Therapeutics, Solstice, CHDI Foundation, Michael J. Fox Foundation, NIH and Medtronic. Dr. Hauser has received personal compensation for activities with Guidepoint Global, SAI-Mmed Partners, Scienomics Group, Gerson Lehrman Group, LCN Consulting, Putnam Associates, National Parkinson Foundation, eResearch Technology, Inc., Lundbeck LLC, Krog & Partners, and Cynapsus as a consultant. Dr. Hauser has received licensing fee payments from the Universit...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Anderson, K. E., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Isojarvi, J., Jimenez-Shahed, J., Ondo, W. G., Fernandez, H. H. Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research